

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 2

PATENT NO. : 7,407,684 B2

APPLICATION NO.: 10/765,065

ISSUE DATE : August 5, 2008

INVENTOR(S) : Spencer et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 2, lines 62-63, "to first" should be changed to --to the first--;
 Column 3, line 45, "difference" should be changed to --differences--;
 Column 3, lines 65-66, "experience" should be changed to --experiences--;
 Column 4, line 59, "section portions" should be changed to --second portions--;
 Column 5, line 66, "while covering" should be changed to --while coating--;
 Column 6, line 17, "medical device" should be changed to --the medical device--;
 Column 7, line 19, "medical device" should be changed to --the medical device--;
 Column 7, line 39, "raneg" should be changed to --range--;
 Column 7, line 39, "S cm-1" should be changed to --S/cm--;

Column 7, line 43, "FeCl₃ or S₂O₈²⁻" should be changed to --FeCl₃ or S₂O₈²⁻--;

Column 7, line 45, "(A-)" should be changed to --A--;

MAILING ADDRESS OF SENDER (Please do not use customer number below):

KENYON AND KENYON
 1500 K Street, N.W., Suite 700
 Washington, D.C. 20005

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No. : 7,407,684 B2
Serial No. : 10/765,065
Applicant : Spencer et al. Confirmation No. 9463
Filed: : January 28, 2004
Art Unit : 1792
Title: : MULTI-STEP METHOD OF MANUFACTURING A MEDICAL
DEVICE
Examiner : Erma Cameron

Attn: Certificate of Corrections Branch

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION PURSUANT TO 37 C.F.R. §1.323

SIR:

Patentee hereby requests that the enclosed Certificate of Correction be issued for the above Patent. The following errors that appear in this patent are of a clerical, typographical or minor nature or character and occurred in good faith. Correction thereof does not involve changes in the patent as would constitute new matter or would require reexamination. In particular:

- Column 2, lines 62-63, "to first" should be changed to --to the first--;
- Column 3, line 45, "difference" should be changed to --differences--;
- Column 3, lines 65-66, "experience" should be changed to --experiences--;
- Column 4, line 59, "section portions" should be changed to --second portions--;
- Column 5, line 66, "while covering" should be changed to --while coating--;
- Column 6, line 17, "medical device" should be changed to --the medical device--;
- Column 7, line 19, "medical device" should be changed to --the medical device--;

Column 7, line 39, “raneg” should be changed to --range--;

Column 7, line 39, “S cm-1” should be changed to --S/cm--;

Column 7, line 43, “FeCl₃ or S₂O₈²⁻” should be changed to --FeCl₃ or S₂O₈²⁻--;

Column 7, line 45, “(A-)” should be changed to --A⁻--;

Column 7, lines 51-52, “a non-genetic therapeutic agents” should be changed to --non-genetic therapeutic agents--;

Column 7, line 63, “estrodinol” should be changed to --estradiol--;

Column 8, line 12, “lisidomine” should be changed to --linsidomine--;

Column 8, line 18, “Warafin” should be changed to --warfarin--;

Column 8, line 18, “Dicumarol” should be changed to --dicumarol--;

Column 8, line 20, “promotors” should be changed to --promoters--;

Column 8, lines 21-22, “promoters” should be changed to --promoters--;

Column 8, line 29, “endogeneus vascoactive” should be changed to --endogenous vasoactive--;

Column 8, line 43, “(“MCP-1) ” should be changed to --(“MCP-1”)--;

Column 8, line 44, “(“BMP’s”) ” should be changed to --(“BMPs”)--;

Column 8, line 47, “BMPS” should be changed to --BMPs--;

Column 8, line 49, “homdimers” should be changed to --homodimers--;

Column 8, line 53, “the “hedghog” proteins” should be changed to --the “hedgehog” proteins--;

Column 8, line 53, “DNA’s” should be changed to --DNAs--;

Column 9, line 2, “have” should be changed to --having--;

Column 9, line 6, “allogenic” should be changed to --allogeneic--;

Column 9, line 7, “xenogenic” should be changed to --xenogeneic--;

Column 9, “(BAYHDROL®)” should be changed to --(BAYHYDROL®)--;

Column 9, line 32, “poly(D,L,-lactide)” should be changed to --poly(D,L-lactide)--; and

Column 9, line 33, “50/50 DL-lactide-co-glycolide)” should be changed to --50/50 D,L-lactide-co-glycolide)--.

The Commissioner is hereby authorized to charge payment of the 37 C.F.R. §1.20(a) Certificate of Correction fee of \$100.00 to the deposit account of Kenyon & Kenyon, deposit account number 11-0600. The Commissioner is also authorized to charge any additional fees or credit any overpayment in connection with this paper to Deposit Account No. 11-0600.

Respectfully submitted,

KENYON & KENYON LLP

Dated: July 8, 2009

/Jocelyn D. Ram/
Jocelyn D. Ram
Reg. No. 54,898

KENYON AND KENYON LLP
1500 K Street, N.W., Suite 700
Washington, D.C. 20005
(202) 220-4200
(202) 220-4201 (Fax)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 2 of 2

PATENT NO. : 7,407,684 B2

APPLICATION NO.: 10/765,065

ISSUE DATE : August 5, 2008

INVENTOR(S) : Spencer et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 7, lines 51-52, "a non-genetic therapeutic agents" should be changed to --non- genetic therapeutic agents--;

Column 7, line 63, "estrodinol" should be changed to --estradiol--;

Column 8, line 12, "lisidomine" should be changed to --linsidomine--;

Column 8, line 18, "Warafin" should be changed to --warfarin--;

Column 8, line 18, "Dicumarol" should be changed to --dicumarol--;

Column 8, line 20, "promotors" should be changed to --promoters--;

Column 8, lines 21-22, "promoters" should be changed to --promoters--;

Column 8, line 29, "endogeneus vasoactive" should be changed to --endogenous vasoactive--;

Column 8, line 43, "(MCP-1)" should be changed to --("MCP-1")--;

Column 8, line 44, "(BMP's)" should be changed to --("BMPs")--;

Column 8, line 47, "BMPS" should be changed to --BMPs--;

Column 8, line 49, "homdimers" should be changed to --homodimers--;

Column 8, line 53, "the "hedghog" proteins" should be changed to --the "hedgehog" proteins--;

Column 8, line 53, "DNA's" should be changed to --DNAs--;

Column 9, line 2, "have" should be changed to --having--;

Column 9, line 6, "allogenic" should be changed to --allogeneic--;

Column 9, line 7, "xenogenic" should be changed to --xenogeneic--;

Column 9, "(BAYHDROL®)" should be changed to --(BAYHYDROL®)--;

Column 9, line 32, "poly(D,L,-lactide)" should be changed to --poly(D,L-lactide)--; and

Column 9, line 33, "50/50 DL-lactide-co-glycolide)" should be changed to --50/50 D,L- lactide-co-glycolide)--.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

KENYON AND KENYON
1500 K Street, N.W., Suite 700
Washington, D.C. 20005

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.